Navigation Links
ARCA biopharma to Present at 27th Annual JPMorgan Healthcare Conference
Date:1/8/2009

d on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro. The New Drug Application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, is currently under review by the U.S. Food and Drug Administration. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. For more information please visit http://www.arcabiopharma.com.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1 development for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at its website at http://www.nuvelo.com or by phoning 650-517-8000.

Forward-looking statements

This press release conta
'/>"/>

SOURCE ARCA biopharma, Inc. and Nuvelo, Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma
2. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
3. Helix BioPharma Announces Q1 2009 Financial Results
4. McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries
5. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
6. XTL Biopharmaceuticals Implements Restructuring Plan
7. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
8. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
9. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
10. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
11. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company ... announced the results of its annual general meeting of ... year in Relmada,s history and it set the stage ... Sergio Traversa , chief executive officer of Relmada. "Over ... human resource and clinical development objectives that position Relmada ...
(Date:12/17/2014)... 2014 Achim Noack has been named ... Group. In this position, Noack will assist Jerry Stoller, ... develop marketing strategy and supervise global marketing management and ... has tremendous knowledge and experience in the crop protection ... experience and innovative thinking will be a great asset ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 17, 2014  United Therapeutics Corporation (NASDAQ: ... well as changes to Martine Rothblatt , Ph.D,s ... United Therapeutics announced the promotion of ... Officer and David Zaccardelli , Pharm.D. to Executive ... these promotions, Dr. Rothblatt,s title will change from Chairman ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... 2011 Reportlinker.com announces that a new market research ... The Future of In Vitro and In ... The term in-vitro/in-vivo diagnostics (IV2D) ... and pathology (imaging), as well as new software ...
... YORK, Jan. 25, 2011 Reportlinker.com announces ... available in its catalogue: ... Implications of Emerging Reimbursement, Technological and Market ... http://www.reportlinker.com/p0365288/Future-US-In-Vitro-Diagnostics-Market-Strategic-Implications-of-Emerging-Reimbursement-Technological-and-Market-Trends-through-2018.html How will ...
... 23, 2011 An interdisciplinary team from Columbia University ... together with researchers from the University,s departments of Physics ... single-molecule interactions on very short time scales using nanoscale ... 23 in Nature Nanotechnology , they show how, ...
Cached Biology Technology:Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 2Reportlinker Adds The Future of In Vitro and In Vivo Diagnostic Integration 3Reportlinker Adds Future US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends Through 2018 2Columbia University researchers use nanoscale transistors to study single-molecule interactions 2
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced ... India 2015-2019" report to their offering. ... market is the adoption of multimodal biometric systems. ... of an individual for verification and identification purposes. ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... Amsterdam, 16 March, 2011 A recent special edition ... Elsevier, on behalf of the British Mycological Society, features a ... collection of fungal cell biology movies ever published. The movies ... Exeter, UK, who is a renowned researcher in the field ...
... analyze the complex ingredients in the new genre of ... for cigarettes in places where smoking is banned have ... The report appears in ACS,s Journal of Agricultural ... colleagues point out that the first dissolvable tobacco products ...
... Trends in Plant Science , provides an overview ... for ecologists, physiologists and molecular biologists, since it covers ... change. The results show that plants in ... to a changing environment without requiring any evolutionary changes, ...
Cached Biology News:New 'dissolvable tobacco' products may increase risk of mouth disease 2Plasticity of plants helps them adapt to climate change 2